Lipidor Reports Update on Patient Enrolment in P-III Clinical Study of AKP02 for the Treatment of Mild to Moderate Psoriasis
Shots:
- The company has enrolled 50% of the patients (i.e., ~147) in the P-III study evaluating the therapeutic effect, QoL & patient satisfaction of AKP02 for the treatment of mild/moderate psoriasis with results expected in Q3’22. Lipidor initiated recruitment in Jan'22
- Lipidor will enroll a total of 294 patients with the last patient expected to initiate treatment in Jun’22. Additionally, Lipidor along with its commercial partner RELIFE are working on AKP01 & AKP02 for the treatment of the same indication in the EU, CIS countries & Turkey
- AKP02 is a combination of calcipotriol + betamethasone dipropionate & is based on Lipidor’s AKVANO technology. Additionally, the company will evaluate AKP02 in comparison with Enstilar
Ref: Cision | Image: Lipidor
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
